Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Financials & AGM Materials

2023

Q1

Quarterly Press Release

Q2

Quarterly Press Release

Financial Statements

MD&A

2022

Q1

Quarterly Press Release

Q2

Quarterly Press Release

Q3

Quarterly Press Release

Q4

Quarterly Press Release

AGM Materials

Form of Proxy – for Registered Shareholders

Notice and Access Notification – Internet Availability

Notice of Meeting and Information Circular

Notice of Meeting

2021

Q1

10-Q

Q2

Quarterly Press Release

10-Q

Q3

Quarterly Press Release

10-Q

Q4

Quarterly Press Release

10-Q

AGM Materials

2021 Annual Report

Form of Proxy – for Registered Shareholders

Notice and Access Notification – Internet Availability

Notice of Meeting and Information Circular

Notice of Meeting

Voting Instruction Form – for non-Registered Shareholders

2020

Q1

Quarterly Press Release

Financial Statements

MD&A

Q2

Quarterly Press Release

Financial Statements

MD&A

Q3

Quarterly Press Release

Financial Statements

MD&A

Q4

Quarterly Press Release

Financial Statements

MD&A

Annual Information Form

AGM Materials

Amended Notice of AGM and Information (Proxy) Circular

Form of Proxy

2019

Q1

Quarterly Press Release

Financial Statements

MD&A

Q2

Quarterly Press Release

Financial Statements

MD&A

Q3

Quarterly Press Release

Financial Statements

MD&A

Q4

Quarterly Press Release

Financial Statements

MD&A

Annual Information Form

AGM Materials

Notice of AGM and Information (Proxy) Circular

Form of Proxy

2018

Q1

Financial Statements

MD&A

Q2

Financial Statements

MD&A

Q3

Quarterly Press Release

Financial Statements

MD&A

Q4

Quarterly Press Release

Financial Statements

MD&A

Annual Information Form

AGM Materials

Notice of AGM and Information (Proxy) Circular

Form of Proxy

Investor Alerts

Sign up for investor alerts!

Information Request

Send us a request for information

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing
BayMedica Cannabinoid Biosynthesis
Rare Cannabinoid Ingredients

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM
Filings
Presentations
Media

CORPORATE

Management
Board of Directors
Scientific Advisory Board
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.